Hotline:
+ 49 (0) 221 677 897 22
Anbieter: Visiongain

Alzheimer's Disease Market analysis and forecasts, 2007-2012, 2017 & 2022

Artikelnummer:16494
Veröffentlichungsdatum:01.10.2007
Sprachversion:Englisch
Studientyp:Marktstudie
Sterne (Bewertung):Für diese Studie liegt keine Bewertung vor.
2.399,40 € (Originalpreis: 3.100,00 $)   *

WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Zt. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs.

* Hier können Sie die Währung umstellen, in der Sie bezahlen möchten.
Screenshots
Alzheimer-Krankheit Marktanalyse und Prognosen, 2007-2012, 2017 und 2022
Mehr über diese Studie
Inhaltsverzeichnis
Weitere relevante Studien
Unsere Garantie
 

Zahlen und Fakten zur Studie

What questions does the report answer?
  • Which regions have the highest prevalence of AD diseases today
  • and by 2050?
  • Do you know the cost of AD across the larger markets?
  • Who are the market leaders in this class of therapy?
  • What market share was accounted for by the quartet of AD drugs in the major markets?
  • Do you know the magnitude of the controversy generated by
  • NICE's, as it deems the major drugs not cost-effective on the NHS?
  • Do you know how much the AD market will be worth by Q4 of 2007
  • and its potential value by 2012, 2017 and 2022?
  • Which first line drugs will be coming off patent by 2012 and what are the economic implications to the market?
  • Do you know which drugs have been withdrawn from the neurodegenerative market?
  • Which molecules are currently in the AD pipelines that are deemed to answer unmet therapeutic needs in the future?


Revenues of the only approved AD drugs across the major markets (US, Japan, France, Germany, Italy, Spain and the UK) totaled over $3 billion in 2006, with revenues expected to exceed $5 billion by 2012. By 2014, Visiongain anticipates that, all the AD approved therapies will come of patents in the major markets signaling a potential genericisation of the AD market.

With looming patient potential over the major products, Visiongain's market analysis forecast a-to- be lucrative era during the mid-term of our forecast where we believe, the sector will see the penetration of highly innovative AD products presently in late-phase clinical studies into the AD arena, only heralded by modest therapies, as opposed to the large outcry for highly effective drugs complimented by value for money by inter-country healthcare regulatory authorities.

With country-by-country focus on the markets of:
- US
- UK
- Japan
- France
- Italy
- Spain

Inhalt der Studie

Alzheimers disease (AD) is the third leading cause of death in recent times and with an unprecedented patient potential, this disease area attracts awareness from a broad base of stake holders. With the grey population being the single most influencial factor in driving the economic growth within this sector, Visiongain believes the real market of the AD industry still remains untapped.

Over the past decade the AD market has been flagged by a quartet of approved pharmacological agents; acetyl cholinesterase inhibitors (AchEIs), N-methyl D-aspartate (NMDA) receptor antagonists and other non-AD specific therapeutics for management of comorbidities. The AchEIs comprise products from some of the leading larger pharmaceutical companies;
Esia/Pfizer's Aricept (Donepizel)
Novartis Exelon (Rivagstigmine) and Shire/J&J's Razadyne (galantamiune) previously Reminyl and
recent entrant a non-AchEI
NMDA receptor antagonist Mementine, marketed in the US by Forest
as Nemanda and in EU as Ebixa by Lundbeck Mementine

However, all the listed drugs only elicited modest clinical benefits in treating the various stages of the AD. In addition, the UK National Institute of Clinical Excellence (NICE) decision not to place the drugs on the NHS for reimbursement generated major controversy across the larger markets, only to affect the potential revenue growth on the major drugs particularly in the UK, one of the significant markets.